Liang Donghai, Zhou Fei, Xu Chen, Zou Lili, Jiang Tao, Lu Haijun, Meng Chunliu
Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Oncology, Second Affiliated Hospital of Qingdao University, Qingdao, China.
Case Rep Oncol. 2025 Feb 19;18(1):372-380. doi: 10.1159/000544788. eCollection 2025 Jan-Dec.
EGFR-sensitive mutations bilateral diffuse lung adenocarcinoma (LUAD) complicated with acute respiratory distress syndrome (ARDS) is relatively rare. It is important to consider whether EGFR-TKI can be simultaneously received when treating with extracorporeal membrane oxygenation (ECMO) and anti-infective therapy in these patients, and what adverse events should be noted?
We report a case of EGFR 19 exon-deficient bilateral diffuse LUAD complicated with ARDS. When treated with ECMO and anti-infective therapy, the patient received oral osimertinib anti-tumor therapy simultaneously. The tumor receded, but eventually irreversible thrombocytopenia developed.
For patients with severe lung cancer, anti-tumor efficacy and adverse events should be closely observed during anti-tumor therapy.
表皮生长因子受体（EGFR）敏感突变的双侧弥漫性肺腺癌（LUAD）合并急性呼吸窘迫综合征（ARDS）相对罕见。对于此类患者，在进行体外膜肺氧合（ECMO）和抗感染治疗时，考虑是否可同时接受EGFR酪氨酸激酶抑制剂（EGFR-TKI）治疗以及应注意哪些不良事件很重要。
我们报告1例EGFR 19外显子缺失的双侧弥漫性LUAD合并ARDS患者。在接受ECMO和抗感染治疗时，该患者同时接受了口服奥希替尼抗肿瘤治疗。肿瘤缩小，但最终出现了不可逆的血小板减少症。
对于重症肺癌患者，在抗肿瘤治疗期间应密切观察抗肿瘤疗效和不良事件。
